J Korean Surg Soc.  2011 Jan;80(1):29-35. 10.4174/jkss.2011.80.1.29.

Expression of E-cadherin, beta-catenin, Cdx2 and MMP7 in pT2 and N1/N2 Gastric Cancer: Relationship with Tumor Recurrence within 2-Year Period

• Kim JH
• Eom DY
• Kim CW
• Choi NK
• Kwak JH
• Choi GM
• Jang HJ
• Han MS

• KMID: 2096616
• DOI: http://doi.org/10.4174/jkss.2011.80.1.29

Abstract

PURPOSE
The aim of this study was to examine the expression of E-cadherin, beta-catenin, Cdx2, MMP7 in gastric cancer and to evaluate the clinical significance of these molecules in tumor recurrence within 2 years of pT2 and N1/N2 gastric cancer.
METHODS
In 122 patients who underwent radical resection of gastric cancer, we investigated the association between the expression of these molecules and clinicopathologic factors by immunohistochemistry. The included criteria were pT2 and N1 or N2 (6th AJCC TNM).
RESULTS
The expression of MMP7 was significantly associated with N stage (N1 vs. N2) (P=0.011). The negative expression of beta-catenin was strongly correlated with tumor recurrence within a 2-year period. However, the expression of these molecules was not related with recurrent sites. Multivariate analysis demonstrated that negative expression of beta-catenin was an independent predictor for tumor recurrence within 2 years (OR 2.366; 95% CI 1.056~5.297; P=0.036).
CONCLUSION
Negative expression of beta-catenin may serve as a significant indicator for predicting tumor recurrence within a 2-year period in pT2 and N1/N2 gastric cancer.

Keyword

E-cadherin; beta-catenin; Cdx2; MMP7; Gastric cancer

MeSH Terms

beta Catenin
Cadherins
Humans
Immunohistochemistry
Multivariate Analysis
Recurrence
Stomach Neoplasms
Cadherins
beta Catenin

Figure

• 

  Fig. 1. Representative images of H&E stain and immunohistochemistry of E-cadherin, β-catenin, Cdx2 and MMP7. (A) Moderately differentiated adenocarcinoma is noted (H&E stain, ×200). (B) The tumor cells are positive in the cell membrane for E-cadherin (Immunohistochemistry, ×400). (C) Aberrant β-catenin expression (cytoplasmic and nuclear accumulation) is noted (Immunohistochemistry, ×400). (D) The tumor cells are positive in the nuclei for Cdx2 (Immunohistochemistry, ×400). (E) The tumor cells are positive in the cytoplasm for the MMP7 (Immunohisto-chemistry, ×400).

Reference

References

1. John M, Peter MH, Mark AI, Joe WG, Craig BT. The Molecular Basis of Cancer. 3rd ed.Philadelphia: Saunders;2008.

2. Joo YE, Rew JS, Kim HS, Choi SH, Park CS, Kim SJ. Changes in the E-cadherin-catenin complex expression in early and advanced gastric cancers. Digestion. 2001; 64:111–9.

3. Yonemura Y, Endou Y, Fujita H, Fushida S, Bandou E, Taniguchi K, et al. Role of MMP-7 in the formation of peritoneal dissemination in gastric cancer. Gastric Cancer. 2000; 3:63–70.

4. Mizoshita T, Tsukamoto T, Nakanishi H, Inada K, Ogasawara N, Joh T, et al. Expression of Cdx2 and the phenotype of advanced gastric cancers: relationship with prognosis. J Cancer Res Clin Oncol. 2003; 129:727–34.

5. Seno H, Oshima M, Taniguchi MA, Usami K, Ishikawa TO, Chiba T, et al. CDX2 expression in the stomach with intestinal metaplasia and intestinal-type cancer: Prognostic implications. Int J Oncol. 2002; 21:769–74.

6. Yoo CH, Noh SH, Shin DW, Choi SH, Min JS. Recurrence following curative resection for gastric carcinoma. Br J Surg. 2000; 87:236–42.

7. Takeichi M. Cadherin cell adhesion receptors as a morphoge-netic regulator. Science. 1991; 251:1451–5.

8. Shiozaki H, Oka H, Inoue M, Tamura S, Monden M. E-cad-herin mediated adhesion system in cancer cells. Cancer. 1996; 77(8 Suppl):1605–13.

9. Suh E, Traber PG. An intestine-specific homeobox gene regulates proliferation and differentiation. Mol Cell Biol. 1996; 16:619–25.

10. Eda A, Osawa H, Yanaka I, Satoh K, Mutoh H, Kihira K, et al. Expression of homeobox gene CDX2 precedes that of CDX1 during the progression of intestinal metaplasia. J Gastroenterol. 2002; 37:94–100.

11. Fan Z, Li J, Dong B, Huang X. Expression of Cdx2 and hepatocyte antigen in gastric carcinoma: correlation with histologic type and implications for prognosis. Clin Cancer Res. 2005; 11:6162–70.

12. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol. 2000; 18:1135–49.

13. Shiomi T, Okada Y. MT1-MMP and MMP-7 in invasion and metastasis of human cancers. Cancer Metastasis Rev. 2003; 22:145–52.

14. Adachi Y, Yamamoto H, Itoh F, Hinoda Y, Okada Y, Imai K. Contribution of matrilysin (MMP-7) to the metastatic pathway of human colorectal cancers. Gut. 1999; 45:252–8.

15. Ajisaka H, Yonemura Y, Miwa K. Correlation of lymph node metastases and expression of matrix metalloproteinase-7 in patients with gastric cancer. Hepatogastroenterology. 2004; 51:900–5.

16. Gabbert HE, Mueller W, Schneiders A, Meier S, Moll R, Birchmeier W, et al. Prognostic value of E-cadherin expression in 413 gastric carcinomas. Int J Cancer. 1996; 69:184–9.

17. Zhou YN, Xu CP, Han B, Li M, Qiao L, Fang DC, et al. Expression of E-cadherin and beta-catenin in gastric carcinoma and its correlation with the clinicopathological features and patient survival. World J Gastroenterol. 2002; 8:987–93.

18. Jawhari A, Jordan S, Poole S, Browne P, Pignatelli M, Farthing MJ. Abnormal immunoreactivity of the E-cadherin-catenin complex in gastric carcinoma: relationship with patient survival. Gastroenterology. 1997; 112:46–54.

19. Chen JQ, Zhan WH, He YL, Peng JS, Wang JP, Cai SR, et al. Expression of heparanase gene, CD44v6, MMP-7 and nm23 protein and their relationship with the invasion and metastasis of gastric carcinomas. World J Gastroenterol. 2004; 10:776–82.

20. Kuramoto M, Shimada S, Ikeshima S, Matsuo A, Yagi Y, Matsuda M, et al. Extensive intraoperative peritoneal lavage as a standard prophylactic strategy for peritoneal recurrence in patients with gastric carcinoma. Ann Surg. 2009; 250:242–6.